布地奈德联合利巴韦林 氨溴索雾化吸入治疗毛细支气管炎的疗效观察

目的观察布地奈德联合利巴韦林、氨溴索雾化吸人治疗毛细支气管炎的疗效。方法将我院160例毛细支气管炎患儿随机分为观察组和对照组,每组80例。两组均给予常规治疗,观察组在常规治疗的基础上给予布地奈德联合利巴韦林、氨溴索雾化吸人治疗,观察两组的临床效果。结果观察组显效率为90．0％,总有效率为100．0％,明显高于对照组的51．3％和78．8％（P〈0．01）;观察组临床症状、体征恢复时间均较对照组明显缩短（P〈0．01）。结论布地奈德联合利巴韦林、氨溴索雾化吸人治疗毛细支气管炎疗效显著,有推广价值。     

Double-blind placebo-controlled randomized clinical trial on the efficacy of Aerosal in the treatment of sub-obstructive adenotonsillar hypertrophy and related diseases

Background

Adenotonsillar hypertrophy (ATH) is a frequent cause of upper airways obstructive syndromes associated to middle ear and paranasal sinuses disorders, swallowing and voice disorders, sleep quality disorders, and occasionally facial dysmorphisms. ATH treatment is essentially based on a number of medical–surgical aids including nasal irrigation with topical antibiotics and corticosteroids and/or treatment with systemic corticosteroids, immunoregulators, thermal treatments, adenotonsillectomy, etc.

Objectives

The aim of the present study is to assess the efficacy of Aerosal^® halotherapy in the treatment of sub-obstructive adenotonsillar disease and correlated conditions compared to placebo treatment.

Methods

A total of 45 patients with sub-obstructive adenotonsillar hypertrophy were randomized to receive either Aerosal^® halotherapy or placebo for 10 treatment sessions. The main outcome was a reduction greater than or equal to 25% from the baseline of the degree of adenoid and/or tonsillar hypertrophy.

Results

In the intention-to-treat analysis, a reduction of the degree of adenoid and/or tonsillar hypertrophy ≥25% from baseline after 10 therapy sessions was found in 44.4% of the patients in the halotherapy arm and in 22.2% of the patients in the placebo arm (P = 0.204). Among the secondary outcomes, the reduction of hearing loss after 10 treatment sessions in the halotherapy arm was higher than the placebo arm (P = 0.018) as well as the time-dependent analysis showed significantly improved peak pressure in the Aerosal^® group (P = 0.038). No side effects were reported during the trial. In addition, the therapy was well accepted by the young patients who considered it as a time for play rather than a therapy.

Conclusions

Aerosal^® halotherapy can be considered a viable adjunct, albeit not a replacement, to conventional medical treatment of sub-obstructive adenotonsillar syndrome and related conditions. Further research is however needed to improve ATH treatment.     

雾化吸入与体位引流结合提高排痰效果的护理观察

目的：探讨雾化吸入与体位引流相结合的排痰效果。方法：随机将102例支气管扩张、肺脓肿患者分为A、B、C3组各34例。A组单纯体位引流；B组单纯雾化吸入；C组在体位引流前雾化吸入。观察记录患者每日的痰液排除量，体温恢复天数，住院天数，以此为临床疗效指标。结果：C组患者的每日排痰量明显高于A组和B组（P〈0．01）；体温恢复天数及住院天数较A组和B组缩短（P〈0．05）。结论：雾化吸入与体位引流结合提高了排痰效果，加快了患者康复。     

急性高压电缆线失火烟雾吸入中毒的临床观察

目的：观察聚氯乙烯电缆线失火烟雾吸入中毒者的临床所见。方法：对１１７例的主要症状与体征等进行分析。结果：主要表现为上呼吸道和眼的刺激，及呼吸、中枢神经和消化系统症状。动脉血和Ｐ显著降低。心电图ＳＴ段改变及传导阻滞发生率较高。结论：症状较轻的多数患者经门诊对症治疗，在１周～１月内症状减轻或消失。１８例重症患者经住院救治，治疗后３月至１．５年，ＣＴ检查４例（２２．２２％）仍残留有肺间质的增生和纤维化     

飞机用2％右旋苯醚菊脂杀虫气雾剂的研究

根据民航局科教司和各航空公司的要求，按照世界卫生组织规定的飞机用杀虫气雾剂试验程序和标准进行研究表明，本气雾剂药效稳定，具有广谱、高效杀虫效果，对人无毒、无害；对飞机材料设备不造成损害；不燃，符合国际标准的要求，达到国外同类产品的质量水平，并制订了本气雾剂民用航空行业标准，现已通过审定、发布、实施。该气雾剂已在国内外民用飞机上推广使用。